Inventiva (NASDAQ:IVA) Reaches New 1-Year High - Here's Why

Key Points

• Inventiva's share price reached a new 52-week high of $5.38, marking a significant rise from its previous close of $4.59, with a trading volume of 5,394 shares.
• Piper Sandler has initiated coverage on Inventiva with an "overweight" rating and a target price of $26.00, contributing to a current average rating of "Moderate Buy" from analysts.
• Institutional investors now own 19.06% of Inventiva's stock, with Creative Planning acquiring a new stake of 10,000 shares valued at approximately $32,000 during the second quarter.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) hit a new 52-week high during trading on Wednesday . The company traded as high as $5.38 and last traded at $5.34, with a volume of 5394 shares trading hands. The stock had previously closed at $4.59.

Analysts Set New Price Targets

Separately, Piper Sandler started coverage on Inventiva in a research note on Wednesday. They issued an "overweight" rating and a $26.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $13.00.

Inventiva Stock Down 2.5%

The company's fifty day moving average price is $3.65 and its 200 day moving average price is $3.36.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.